{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T12:48:20Z","timestamp":1789908500601,"version":"4.0.1"},"reference-count":22,"publisher":"SAGE Publications","issue":"9","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2013,9]]},"abstract":"<jats:p>Background: Subcutaneous bortezomib is noninferior in efficacy to intravenous bortezomib and is associated with a lower incidence of neuropathy in the treatment of multiple myeloma. However, there are no data assessing the effect of subcutaneous bortezomib administration on practice variables or patient preferences. Objective: To quantify the difference in efficiency practice variables and patient preferences regarding subcutaneous versus intravenous bortezomib administration in patients with multiple myeloma. Methods: This study was divided into 2 parts consisting of mutually exclusive patients: a retrospective efficiency study and a survey study. Patients\u2019 medical records were reviewed for efficiency data measures including length of infusion chair time and overall infusion center visit time in patients who received at least 6 doses of bortezomib. Patients who received at least 1 dose each of subcutaneous and intravenous administration were surveyed regarding preference, satisfaction, injection site reactions, and quality of life measures. A database was used to identify eligible patients for each portion of the study. Results: A review of 92 medical records demonstrated a 38% reduction in chair time (143 vs 89 minutes; p &lt; 0.001) and a 27% reduction in infusion center visit time (169 vs 123 minutes; p &lt; 0.001) with subcutaneous versus intravenous administration of bortezomib. Of 47 eligible patients, 60% (28) completed the survey; 68% (19; p = 0.0002) of these patients preferred and were more satisfied with subcutaneous bortezomib administration. The overall incidence of injection site reactions was 39% (11) in the surveyed population and was not significantly different between the 2 preference groups. Limitations of the study include single-center design, small sample size, and nonvalidated survey. Conclusions: Subcutaneous administration of bortezomib is more time efficient for the patient and institution and is preferred by patients compared to intravenous bortezomib.<\/jats:p>","DOI":"10.1177\/1060028013503122","type":"journal-article","created":{"date-parts":[[2014,7,15]],"date-time":"2014-07-15T13:56:59Z","timestamp":1405432619000},"page":"1136-1142","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":34,"title":["Subcutaneous Versus Intravenous Bortezomib"],"prefix":"10.1177","volume":"47","author":[{"given":"Meagan S.","family":"Barbee","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Services, Emory Healthcare, Atlanta, GA"},{"name":"Mercer University College of Pharmacy and Health Sciences, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Donald","family":"Harvey","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagar","family":"Lonial","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan L.","family":"Kaufman","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole M.","family":"Wilson","sequence":"additional","affiliation":[{"name":"Mercer University College of Pharmacy and Health Sciences, Atlanta, GA"},{"name":"Hematology\/Oncology, Department of Pharmaceutical Services, Emory Healthcare, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor","family":"McKibbin","sequence":"additional","affiliation":[{"name":"Mercer University College of Pharmacy and Health Sciences, Atlanta, GA"},{"name":"Hematology\/Oncology, Department of Pharmaceutical Services, Emory Healthcare, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald A.","family":"Hutcherson","sequence":"additional","affiliation":[{"name":"Mercer University College of Pharmacy and Health Sciences, Atlanta, GA"},{"name":"Hematology\/Oncology, Department of Pharmaceutical Services, Emory Healthcare, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minal","family":"Surati","sequence":"additional","affiliation":[{"name":"Hematology\/Oncology, Department of Pharmaceutical Services, Emory Healthcare, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Valla","sequence":"additional","affiliation":[{"name":"Hematology\/Oncology, Department of Pharmaceutical Services, Emory Healthcare, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine Sanvidge","family":"Shah","sequence":"additional","affiliation":[{"name":"Hematology\/Oncology, Department of Pharmaceutical Services, Emory Healthcare, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2013,9,1]]},"reference":[{"key":"bibr1-1060028013503122","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.0723601"},{"key":"bibr2-1060028013503122","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116129"},{"key":"bibr3-1060028013503122","unstructured":"Howlader N, Noone AM, Krapcho M, SEER cancer statistics review, 1975-2009 (vintage 2009 populations), National Cancer Institute. Bethesda, MD. http:\/\/seer.cancer.gov\/csr\/1975_2009_pops09\/ (accessed 2012 Nov 1)."},{"key":"bibr4-1060028013503122","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2648.2003.02722_1.x"},{"key":"bibr5-1060028013503122","first-page":"1","volume":"19","author":"Beurhaus P","year":"2001","journal-title":"Nursing Econ"},{"key":"bibr6-1060028013503122","unstructured":"Anderson KC, Alsina M, Bensinger W, NCCN Clinical Practice Guidelines in Oncology. Multiple myeloma. V.2. 2013. www.nccn.org (accessed 2013 Apr 21)."},{"key":"bibr7-1060028013503122","unstructured":"Product information. Velcade (bortezomib). Cambridge, MA: Millennium Pharmaceuticals, Inc., October 2012."},{"key":"bibr8-1060028013503122","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.13285"},{"key":"bibr9-1060028013503122","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70081-X"},{"key":"bibr10-1060028013503122","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.067793"},{"key":"bibr11-1060028013503122","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70098-5"},{"key":"bibr12-1060028013503122","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-011-0078-x"},{"key":"bibr13-1060028013503122","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-149385"},{"key":"bibr14-1060028013503122","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.7779"},{"key":"bibr15-1060028013503122","doi-asserted-by":"publisher","DOI":"10.1186\/1471-230X-10-1"},{"key":"bibr16-1060028013503122","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep354"},{"key":"bibr17-1060028013503122","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2007.0251"},{"key":"bibr18-1060028013503122","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.318.7179.318"},{"key":"bibr19-1060028013503122","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12055"},{"key":"bibr20-1060028013503122","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2012.05.002"},{"key":"bibr21-1060028013503122","doi-asserted-by":"publisher","DOI":"10.1177\/2040620711432020"},{"key":"bibr22-1060028013503122","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-012-0010-0"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028013503122","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1060028013503122","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028013503122","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:13:07Z","timestamp":1777374787000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1060028013503122"}},"subtitle":["Efficiency Practice Variables and Patient Preferences"],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["10.1177\/1060028013503122"],"URL":"https:\/\/doi.org\/10.1177\/1060028013503122","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9]]}}}